AIM
BSTC

Advantage Investment Management’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Advantage Investment Management’s Portfolio BSTC Stock Details BSTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$51K Hold
957
– – 0.04% 335
2019
Q2 		$57K Buy
957
+278
+41% +$17.5K 0.04% 321
2019
Q1 		$42K Buy
+679
New +$44.9K 0.03% 380

Other funds holding BSTC

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Advantage Investment Management's BSTC Position: Q3 2019 in Review

Advantage Investment Management held its BioSpecifics Technologies Corp. (BSTC) position steady in Q3 2019 at 957 shares worth $51K. The position accounts for 0.04% of the portfolio, ranked #335.

Advantage Investment Management first reported a position in BSTC in Q1 2019 and has held it in 3 quarters since. The position peaked at $57K in Q2 2019. 114 funds tracked by Wall St. Rank hold BSTC as of Q3 2019.

  • Advantage Investment Management held 957 shares of BioSpecifics Technologies Corp. worth $51K as of Q3 2019.
  • Advantage Investment Management left its BioSpecifics Technologies Corp. share count unchanged in Q3 2019.
  • BioSpecifics Technologies Corp. made up 0.04% of Advantage Investment Management's portfolio in Q3 2019, its #335 holding.
  • Advantage Investment Management first reported a position in BioSpecifics Technologies Corp. in Q1 2019 and has held it in 3 quarters since.
  • Advantage Investment Management's BioSpecifics Technologies Corp. position peaked at $57K in Q2 2019.
  • 114 funds tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q3 2019.

Based on Advantage Investment Management's 13F filing for Q3 2019, filed 8 Oct 2019.